based on the fdacalendar below, the earliest the migraine product can get approval would be september
since it isn't on their schedule below.
08/18/2014 Regeneron Pharmaceuticals REGN EYLEA (sBLA) FDA decision on EYLEA for the treatment of Diabetic Macular Edema
08/09/2014 Spectrum Pharmaceuticals Inc SPPI Beleodaq (NDA) FDA decision on Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
08/06/2014 The Medicines Co. MDCO Oritavancin (NDA) FDA decision on Oritavancin for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria
07/29/2014 Anacor Pharmaceuticals, Inc. ANAC Tavaborole (NDA) FDA decision on Tavaborole for the topical treatment of onychomycosis
07/27/2014 AcelRx Pharmaceuticals Inc. ACRX Zalviso (NDA) FDA decision on Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting
07/22/2014 Eagle Pharmaceuticals Inc EGRX Ryanodex (NDA) FDA decision on Ryanodex treatment of malignant hyperthermia
07/16/2014 Salix Pharmaceuticals Ltd SLXP Ruconest (BLA) FDA decison on Ruconest for the treatment of acute angioedema attacks in patients with hereditary angioedema
7/15/2014 MannKind Corp. MNKD AFREZZA Inhalation Powder (NDA) FDA decision on AFREZZA Inhalation Powder to improve glycemic control in adult patients suffering from type I or type II diabetes
Edward, still think ETRM is a great company? I told you what you had their, poor clinical data and a 1 product company that will never be able to sell its product. You got lucky with MNKD, but just because you got lucky once, don't start thinking you have real smarts because you do not. IGXT in a year will be way above and beyond your ETRM. So much for your great company list.